A previous study identified BTYNB as a potent and selective inhibitor of IGF2BP1 binding to c-Myc mRNA and effectively inhibited the proliferation of IGF2BP1-expressing ovarian cancer and melanoma cells with no effect in IGF2BP1-negative cells.17 This evidence concerns the gene IGF2BP1 and ovarian carcinoma.